In vitro Efficacy of Novel Glucan Synthase Inhibitor, Ibrexafungerp (SCY-078), Against Multidrug- and Pan-resistant Candida auris Isolates from the Outbreak in New York
Y. C. Zhu, S. A. Barat, K. Borroto-Esoda, D. Angulo, S. Chaturvedi, V. Chaturvedi
Abstract
We report low MIC50 of Ibrexafungerp (SCY-078) for 102 Candida auris clinical and surveillance isolates from outbreak in New York. The group included C. auris with a variable resistance to antifungal drugs. Five pan-resistant C. auris isolates were susceptible to Ibrexafungerp with low MIC50 range of 0.12-1 {micro}g/ml.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Pan-resistant Candida auris: New York Sub-cluster Susceptible to Antifungal Combinations
B. O'Brien, J. Liang, … V. Chaturvedi·bioRxiv·Jun 8, 2020
- Combinations of antifungals to effectively kill drug-resistant Candida auris
S. Jaggavarapu, E. M. Burd, D. S. Weiss·bioRxiv·Sep 26, 2019
- Synergistic Activity of Minocycline and Rifampin in Combination with Antifungal Drugs against Candida auris
T. Brennan-Krohn, L. Friar, … J. E. Kirby·bioRxiv·Feb 23, 2021
- In vitro Evaluation of Antifungal Drug Combinations against Multidrug-resistant Candida auris isolates from New York Outbreak
B. O'Brien, S. Chaturvedi, V. Chaturvedi·bioRxiv·Oct 31, 2019
- Evaluation of in vitro activity of manogepix against multidrug-resistant and pan-resistant Candida auris from the New York Outbreak
Y. Zhu, S. Kilburn, … V. Chaturvedi·bioRxiv·Jun 2, 2020
- In vitro activity of a novel antifungal compound, MYC-053, against clinically significant antifungal-resistant strains of Candida glabrata, Candida auris, Cryptococcus neoformans, and Pneumocystis spp.
G. Tetz, M. Collins, … V. Tetz·bioRxiv·Sep 6, 2018